Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016


#745899

179pages

DelveInsight

$ 1750

In Stock

DelveInsights, Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Estrogen Receptor Positive (ER+) Breast Cancer. The report provides the in-depth analysis of the pipeline assets across the Estrogen Receptor Positive (ER+) Breast Cancer. The Report gives insights on 40+ products. It also includes around 30+ companies which are active in this field. DelveInsights, Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Estrogen Receptor Positive (ER+) Breast Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Estrogen Receptor Positive (ER+) Breast Cancer.
These days companies are focusing on the Targeted Therapy for cancer. Ipsens Triptorelin pamoate is the Gonadotropin-releasing hormone (GnRH) Agonist in Phase III stage, Seattle Geneticss SGN-LIV1A, is a monoclonal antibody in Phase I are competing against other small molecules. Many big pharmaceuticals companies are involved in ER Breast Cancer. Compared to other cancers, breast cancers show marked resistance to conventional forms of chemotherapy, and there are limited capabilities to diagnose and treat the disease in its earliest stages. No current treatment option has demonstrated long-term benefit in patients with advanced disease who are not eligible for surgery, which represents the majority (80%) of breast cancer cases. Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Landscape across the globe
The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for ER Positive Breast Cancer and also provide company profiling
Pipeline products coverage based on various stages of development from NDA filings to discovery.
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Table of Contents

Breast cancer Overview
Signs and symptoms
Diagnosis
Treatment
Breast Cancer Trends and Future Prospects
Market Barriers
Market Drivers
Pipeline Therapeutics
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Product Description
Research and Development
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Companies Involved in Therapeutic Development
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of Tables

Table 1:Number of Products Under Development for Estrogen Receptor Positive (ER+) Breast Cancer , 2016
Table 2: Number of Products under Development by Companies, 2016
Table 3: Last Stage Products (Phase III and Filed),2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I and IND), 2016
Table 6: Assessment by Monotherapy Products, 2016
Table 7:Assessment by Route Of Administration, 2016
Table 8:Assessment by Stage and Route Of Administration, 2016
Table 9:Assessment by Molecule Type, 2016
Table 10:Assessment by Stage and Molecule Type, 2016
Table 11:Dormant Products, 2016
Table 12: Discontinued Products
Table 13: Companies under development for therapeutic drugs, 2016

List of Figures
Figure 1:Treatment Algorithm for Breast Cancer, 2016
Figure 2: Number of Products under Development for Estrogen Receptor Positive (ER+) Breast Cancer ,2016
Figure 3:Last Stage Products (Phase III), 2016
Figure 4: Mid Stage Products (Phase II),2016
Figure 5: Early Stage Products (Phase I and IND), 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Route of Administration, 2016
Figure 8: Assessment by Stage and Route of Administration, 2016
Figure 9: Assessment by Molecule Type, 2016
Figure 10:Assessment by Stage and Molecule Type, 2016
Figure 11:Dormant Products, 2016